UNSPSC 51331605: Fananserin

This classification denotes a serotonin antagonist with the molecular formula C23H24FN3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 38QJ762ET6, chemically known as 2h-naphth(1,8-cd)isothiazole, 2-(3-(4-(4-fluorophenyl)-1-piperazinyl)propyl)-, 1,1-dioxide but generally known as fananserin, which bears US NIH Compound Identifier 60785. European Medicines Agency schedules Fananserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07507MIG.

UNSPSC 51331605 Fananserin, a Commodity code, does not align with the state and local procurement activity tagged under it. The recent opportunities record shows solicitations for naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription program capabilities—none of which relate to fananserin, a specific pharmaceutical compound. The code shows minimal relevant recent activity, and the opportunities present indicate a systematic mismatch between the UNSPSC classification and the actual goods and services being procured.

The three recent opportunities span different issuing bodies and procurement mechanisms but address broader pharmaceutical and opioid-response supply chains rather than fananserin specifically. Seminole County, Florida issued an IFB (IFB60459723LAS) in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities with a March 26, 2026 deadline. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs. The geographic spread includes Florida, Minnesota, Texas, and Oregon (through MMCAP), but the procurement focus remains on opioid interventions, generic pharmaceutical supply chains, and pharmacy benefit model innovation rather than fananserin as a targeted commodity.